Author(s):
Julaeha Julaeha, Umi Athiyah, Andi Hermansyah
Email(s):
jula002@brin.go.id , umi-a@ff.unair.ac.id , andi-h@ff.unair.ac.id
DOI:
10.52711/0974-360X.2025.00691 
Address:
Julaeha Julaeha1, Umi Athiyah2, Andi Hermansyah2*
1Research Center for Preclinical and Clinical Medicine, Research Organization for Health, National Research and Innovation Agency Republic of Indonesia, Bogor 16911, West Java, Indonesia.
2Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, East Java, Indonesia.
*Corresponding Author
Published In:
Volume - 18,
Issue - 10,
Year - 2025
ABSTRACT:
Individuals with schizophrenia who take atypical antipsychotic agents have often suffered from metabolic syndrome (MetS). Weight gain is the earliest symptom of metabolic syndrome in schizophrenia patient treated with atypical antipsychotic. Weight gain and obesity lead to increased cardiovascular disease, poor quality of life, and treatment non-adherence. The likelihood of MetS necessitates a routine metabolic screening, monitoring, education of lifestyle and multi-disciplinary collaboration. Incorporating pharmacist has been evident to improve this process outcome. Therefore, this study evaluated the outcome of pharmacist intervention under the Education and Metabolic Syndrome Screening (EMESYS) program. This prospective, 3-month, pretest-posttest study recruited 46 patients taking atypical antipsychotics from a mental health hospital in Surabaya Indonesia. Data about medication adherence, lifestyle parameters, metabolic syndrome parameters, risk of cardiovascular diseases and quality of life were collected. No significant improvement was found in metabolic syndrome and quality of life (p>0.05). However, statistical differences were found in the medication adherence and several parameters of lifestyle improvement such physical activities, alcohol intake, healthy diet, obesity and risk of cardiovascular diseases (p<0.05). Pharmacist involvement can be valuable to better control lifestyle parameters, improve medication adherence and reduce the risk of cardiovascular diseases. These are fundamentals in the comprehensive care of patients with schizophrenia.
Cite this article:
Julaeha Julaeha, Umi Athiyah, Andi Hermansyah. The effect of Pharmacist-led Education and Metabolic Syndrome Screening (EMESYS) on the Clinical Outcome, Adherence, and Quality of Life in Patient with Schizophrenia. Research Journal of Pharmacy and Technology. 2025;18(10):4795-2. doi: 10.52711/0974-360X.2025.00691
Cite(Electronic):
Julaeha Julaeha, Umi Athiyah, Andi Hermansyah. The effect of Pharmacist-led Education and Metabolic Syndrome Screening (EMESYS) on the Clinical Outcome, Adherence, and Quality of Life in Patient with Schizophrenia. Research Journal of Pharmacy and Technology. 2025;18(10):4795-2. doi: 10.52711/0974-360X.2025.00691 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-10-30
REFERENCES:
1. Mohammed Anas. I. Effect of Token Economy on Self care Management of Patients with Schizophrenia. Int. J. Adv. Nur. Management. 2016; 4(4): 334-338. doi: 10.5958/2454-2652.2016.00075.5
2. Peritogiannis V. Ninou., Samakouri M. Mortality in Schizophrenia-Spectrum Disorders: Recent Advances in Understanding and Management. Healthcare (Basel). 2022; 10(12): 2366. doi:10.3390/healthcare10122366
3. Ishan I. Panchal, Dhrubo Jyoti Sen, Rakesh S. Parmar, Samir K. Shah. Schizophrenia: Treatment and Future aspects: a Systemic Review. Asian J. Research Chem. 2012; 5(12): 1503-1512.
4. Hutton P. Di Rienzo F. Turkington D. Spencer H. Taylor P. Suicidal Ideation in People With Psychosis Not Taking Antipsychotic Medication: Do Negative Appraisals and Negative Metacognitive Beliefs Mediate the Effect of Symptoms?. Schizophr Bull. 2019; 45(1):37-47. doi:10.1093/schbul/sby153
5. Dayabandara M. Hanwella R. Ratnatunga S. Seneviratne S. Suraweera C. de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017; 13: 2231-2241. doi:10.2147/NDT.S113099
6. Varshita Veerni Jaya Ratna, Monika Vempadapu, Raj kiran Kolakota, Vinodkumar Mugada. Risk of Cardiovascular Disease in Schizophrenia: A Mini Review. Asian J. Res. Pharm. Sci. 2019; 9(2): 131-136. doi: 10.5958/2231-5659.2019.00019.5
7. Julaeha J. Athiyah U. Ayuningtyas JP. Yuliana V. and Hermansyah A. Metabolic Syndrome Risk Associated with Atypical Antipsychotic Medication: A Case Report. Journal of Drug Delivery and Therapeutics. 2021; 11(1): 77-79. DOI:https://doi.org/10.22270/jddt.v11i1.4680.
8. Herlina T. Perwitasari DA. Dania H. Yuliani S. Barliana M. Atypical Antipsychotic Induced Weight Gain in Schizophrenic Patients. Indonesian Journal of Clinical Pharmacy. 2021; 10(1): 57-61. https://doi.org/10.15416/ijcp.2021.10.1.57
9. Julaeha J. Yuliana V. and Ayuningtyas JP. Trend in the Utilization of Antipsychotics in the National Health Coverage Era in Indonesia: A Cross-Sectional Study. Borneo Journal of Pharmacy. 2024; 7(2): 224–232. https://doi.org/10.33084/bjop.v7i2.4909
10. Putri DH. Julaeha J. and Sugianto A. Evaluation of antipsychotic side effects on schizophrenia patients at Dr Radjiman Wediodiningrat Hospital, Indonesia. Pharmacy Education.. 2024; 24(3): 191–196. https://doi.org/10.46542/pe.2024.243.191196
11. Finley PR. Crismon ML. and Rush AJ. Evaluating the impact of pharmacists in mental health: a systematic review. Pharmacotherapy. 2003; 23: 1634-1644.
12. Julaeha J. Athiyah U. Yuliana V. Ayuningtyas JP. Hermansyah A. Schizophrenia, Metabolic Syndrome and the Opportunity for developing Pharmacist-led Toolkit for Education and Metabolic Syndrome Screening (EMESYS): A Review. International Journal of Pharmaceutical Research. 2021; 13(2): 3407-3414. https://doi.org/10.31838/ijpr/2021.13.02.154
13. Julaeha J. Athiyah U. Yuliana V. Ayuningtyas JP. Hermansyah A. Revisiting the intractable barriers affecting medication adherence among outpatients with schizophrenia. 2020; 14(5): 200-205.
14. Khoo CM. Tan ML. Wu Y. et al. Prevalence and control of hypercholesterolaemia as defined by NCEP-ATPIII guidelines and predictors of LDL-C goal attainment in a multi-ethnic Asian population. Ann Acad Med Singap. 2013; 42(8): 379-387.
15. Jahangiry L. Farhangi MA. and Rezaei F. Framingham risk score for estimation of 10-years of cardiovascular diseases risk in patients with metabolic syndrome. Journal of health, population, and nutrition. 2017; 36(1): 36.
16. Julaeha J. Athiyah U. Maramis M. Sugianto A. Hermansyah A. Translation and cross-cultural adaption of an instrument measuring patient’s well-being under treatment for schizophrenia. Journal of Basic and Clinical Physiology and Pharmacology. 2021; 32(4): 341-347. https://doi.org/10.1515/jbcpp-2021-0002
17. Adelufosi AO. Adebowale TO. Abayomi O. and Mosanya JT. Medication adherence and quality of life among Nigerian outpatients with schizophrenia. General Hospital Psychiatry. 2012; 34(1): 72–79.
18. Tan YM. Chong CP. Cheah YC. Impact of hospital pharmacist-led home medication review program for people with schizophrenia: A prospective study from Malaysia. J Appl Pharm Sci. 2019; 9(07):034–041.
19. Yalçin N. Ak S. Gürel ŞC. Çeliker A. Compliance in schizophrenia spectrum disorders: the role of clinical pharmacist. Int Clin Psychopharmacol. 2019; 34(6): 298-304. doi:10.1097/YIC.0000000000000280
20. Marteene W. Winckel K. Hollingworth S. Kisely S. Gallagher E. Hahn M. Ebdrup BH. Firth J. and Siskind D. Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia. Expert Opinion On Drug Safety. 2019; 18(12): 1149–1160.
21. Budreviciute A. Damiati S. Sabir DK. Onder K. Schuller-Goetzburg P. Plakys G. Katileviciute A. Khoja S. and Kodzius R. Management and Prevention Strategies for Non-communicable Diseases (NCDs) and Their Risk Factors. Frontiers in Public Health. 2020; 8: 574111.
22. Kim SW. Kim HJ. Min K. Lee H. Lee SH. Kim S. Kim JS. and Oh B. The relationship between smoking cigarettes and metabolic syndrome: A cross-sectional study with non-single residents of Seoul under 40 years old. PloS one. 2021; 16(8):e0256257.
23. Neha Patel, Ravindra H.N. Impact of Health Education Programme on knowledge regarding prevention of complications of diabetic mellitus among diabetes veterans at selected old age home of Baroda. Asian J. Nur. Edu. and Research. 2015; 5(3): 405-412. doi: 10.5958/2349-2996.2015.00081.6
24. Peiris CL. van Namen M. and O'Donoghue G. Education-based, lifestyle intervention programs with unsupervised exercise improve outcomes in adults with metabolic syndrome. A systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders. 2021; 22 (4): 877–890.
25. Mukherjee S. Skrede S. Milbank E. Andriantsitohaina R. López M. and Fernø J. Understanding the Effects of Antipsychotics on Appetite Control. Frontiers in Nutrition. 2022; 8: 815456.
26. Pillinger T. McCutcheon RA. Vano L. Mizuno Y. Arumuham A. Hindley G. Beck K. Natesan S. Efthimiou O. Cipriani, A. and Howes OD. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The Lancet. Psychiatry. 2020; 7(1): 64–77.
27. Ringen PA. Engh JA. Birkenaes AB. Dieset I. and Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Frontiers in Psychiatry. 2014; 5: 137.
28. Suresh V , Janki B Patel , Sandhya Kumari, Shukal Sonal, Sharma Shivangi, Suthariya Hetal, Sachin Sharma. Assess the Effectiveness of Structured Health Education Programme Regarding Obesity among Adults Residing at Waghodia Taluka. Int. J. Adv. Nur. Management. 2016; 4(4): 372-374. doi: 10.5958/2454-2652.2016.00083.4
29. Bobes J. Garcia-Portilla MP. Bascaran MT. Saiz PA. and Bousoño M. Quality of life in schizophrenic patients. Dialogues in Clinical Neuroscience. 2007; 9(2): 215–226.
30. Ritsner M. Gibel A. Perelroyzen G. Kurs R. Jabarin M. and Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. Journal of Clinical Psychopharmacology. 2004; 24(6):582–591.
31. Widschwendter CG. Kemmler G. Rettenbacher MA. Yalcin-Siedentopf N. and Hofer A. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication. BMC Psychiatry. 2018; 18(1): 212.
32. Vothknecht S. Schoevers RA. and de Haan L. Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review. The Australian and New Zealand journal of psychiatry. 2011; 45(3):182–192.
33. Kanjanasilp J. and Ploylearmsang C. A short term outcomes of pharmaceutical care in Thai patients with schizophrenia : a randomized controlled trial. Songklanakarin J. Sci. Technol. 2016; 38(2): 189-197.
34. Yuliana V. Setiadi AP. Ayuningtyas JP. Effect of Pharmacist Counseling on Medication Adherence and Quality of Life of Schizophrenic Patients in Menur Mental Hospital, Surabaya. Indonesian Journal of Clinical Pharmacy. 2019; 8(3): 196-204.
35. Teetharatkul T. Vitayanont A. Liabsuetrakul T. and Aunjitsakul W. Associations between symptom severity and well-being among Thai patients with schizophrenia: a cross-sectional analytical study. BMC Psychiatry. 2021; 21(1): 348.
36. Josephine Gracia Britto, Ramachandra. Relapse Prevention among Caregivers of Patients with Schizophrenia. Asian J. Nur. Edu. and Research. 2014; 4(1): 140-144.
37. Bincy Kurian, Preeti Mathew, Bivin JB. Impact of Having a Family Member with Major Mental Illness: Do there exists Differences perceived among Spouse- and non-spouse family members?. Asian J. Nur. Edu. and Research. 2017; 7(2): 163-167. doi: 10.5958/2349-2996.2017.00033.7
38. Archana Das, Hiramoni Barman, Lt Col M Jayalakshmi. Burden and Psychological well-being among the primary Caregivers of Schizophrenia. Int. J. of Advances in Nur. Management. 2021; 9(2): 113-120. doi: 10.5958/2454-2652.2021.00029.9
39. Nimmy Andrews, Bivin J B. Development of Home Management Checklist-Schizophrenia (HMCL-S) for Family Caregivers of Persons Diagnosed With Schizophrenia. Asian J. Nur. Edu. and Research.. 2017; 7(2): 235-238. doi: 10.5958/2349-2996.2017.00049.0
40. Hartley M. Lifestyle modification as first line of treatment for chronic disease. Journal of Diabetes, Metabolic Disorders and Control. 2014; 1(2): 35-39.
41. Padmaja A, Mohanasundari S K, Munuswamy, Murali, K. Sesha Kumar. Evaluate The effectiveness of Awareness programme with health Education on breast cancer and skill Training on breast self-Examination among rural women in chittoor Dist Andhra Pradesh-A Collaborative Research. Asian J. Nursing Education and Research. 2020; 10(1): 97-102. doi: 10.5958/2349-2996.2020.00022.1